Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1981 2
1983 4
1985 1
1986 1
1987 3
1988 2
1989 2
1990 4
1997 2
1998 1
1999 1
2000 1
2002 1
2003 3
2005 2
2007 2
2008 1
2011 1
2012 3
2013 1
2014 4
2015 1
2016 4
2017 1
2018 3
2019 2
2020 1
2021 2
2022 2
2023 1
2024 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

57 results

Results by year

Filters applied: . Clear all
Page 1
Olanzapine. Pharmacokinetic and pharmacodynamic profile.
Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. Callaghan JT, et al. Clin Pharmacokinet. 1999 Sep;37(3):177-93. doi: 10.2165/00003088-199937030-00001. Clin Pharmacokinet. 1999. PMID: 10511917 Review.
Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy.
Crews KR, Monte AA, Huddart R, Caudle KE, Kharasch ED, Gaedigk A, Dunnenberger HM, Leeder JS, Callaghan JT, Samer CF, Klein TE, Haidar CE, Van Driest SL, Ruano G, Sangkuhl K, Cavallari LH, Müller DJ, Prows CA, Nagy M, Somogyi AA, Skaar TC. Crews KR, et al. Among authors: callaghan jt. Clin Pharmacol Ther. 2021 Oct;110(4):888-896. doi: 10.1002/cpt.2149. Epub 2021 Feb 9. Clin Pharmacol Ther. 2021. PMID: 33387367 Free PMC article.
The INGENIOUS trial: Impact of pharmacogenetic testing on adverse events in a pragmatic clinical trial.
Eadon MT, Rosenman MB, Zhang P, Fulton CR, Callaghan JT, Holmes AM, Levy KD, Gupta SK, Haas DM, Vuppalanchi R, Benson EA, Kreutz RP, Tillman EM, Shugg T, Pierson RC, Gufford BT, Pratt VM, Zang Y, Desta Z, Dexter PR, Skaar TC. Eadon MT, et al. Among authors: callaghan jt. Pharmacogenomics J. 2023 Nov;23(6):169-177. doi: 10.1038/s41397-023-00315-w. Epub 2023 Sep 9. Pharmacogenomics J. 2023. PMID: 37689822 Free PMC article. Clinical Trial.
PharmGKB summary: uric acid-lowering drugs pathway, pharmacodynamics.
McDonagh EM, Thorn CF, Callaghan JT, Altman RB, Klein TE. McDonagh EM, et al. Among authors: callaghan jt. Pharmacogenet Genomics. 2014 Sep;24(9):464-76. doi: 10.1097/FPC.0000000000000058. Pharmacogenet Genomics. 2014. PMID: 24915143 Free PMC article. Review. No abstract available.
Implementation of a pharmacogenomics consult service to support the INGENIOUS trial.
Eadon MT, Desta Z, Levy KD, Decker BS, Pierson RC, Pratt VM, Callaghan JT, Rosenman MB, Carpenter JS, Holmes AM, McDonald CA, Benson EA, Patil AS, Vuppalanchi R, Gufford BT, Dave N, Robarge JD, Hyder MA, Haas DM, Kreutz RP, Dexter PR, Skaar TC, Flockhart DA. Eadon MT, et al. Among authors: callaghan jt. Clin Pharmacol Ther. 2016 Jul;100(1):63-6. doi: 10.1002/cpt.347. Epub 2016 Mar 31. Clin Pharmacol Ther. 2016. PMID: 26850569 Free PMC article. Review.
Implementing a pragmatic clinical trial to tailor opioids for chronic pain on behalf of the IGNITE ADOPT PGx investigators.
Skaar TC, Myers RA, Fillingim RB, Callaghan JT, Cicali E, Eadon MT, Elwood EN, Ginsburg GS, Lynch S, Nguyen KA, Obeng AO, Park H, Pratt VM, Rosenman M, Sadeghpour A, Shuman S, Singh R, Tillman EM, Volpi S, Wiisanen K, Winterstein AG, Horowitz CR, Voora D, Orlando L, Chakraborty H, Van Driest S, Peterson JF, Cavallari LA, Johnson JA, Dexter PR; IGNITE Pragmatic Trials Network. Skaar TC, et al. Among authors: callaghan jt. Clin Transl Sci. 2024 Aug;17(8):e70005. doi: 10.1111/cts.70005. Clin Transl Sci. 2024. PMID: 39177194 Free PMC article. Clinical Trial.
The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective.
Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach SR, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA; Pharmaceutical Research and Manufacturers of America Drug Metabolism/Clinical Pharmacology Technical Working Groups. Bjornsson TD, et al. Among authors: callaghan jt. J Clin Pharmacol. 2003 May;43(5):443-69. J Clin Pharmacol. 2003. PMID: 12751267 Review.
Response to Gammal et al.
Vassy JL, Stone A, Callaghan JT, Mendes M, Meyer LJ, Pratt VM, Przygodzki RM, Scheuner MT, Wang-Rodriguez J, Schichman SA; VHA Clinical Pharmacogenetics Subcommittee. Vassy JL, et al. Among authors: callaghan jt. Genet Med. 2019 Aug;21(8):1888-1889. doi: 10.1038/s41436-018-0422-9. Epub 2019 Jan 12. Genet Med. 2019. PMID: 30635623 No abstract available.
A pharmacokinetic profile of nizatidine in man.
Callaghan JT, Bergstrom RF, Rubin A, Chernish S, Crabtree R, Knadler MP, Obermeyer B, Offen WW, Schneck DW, Aronoff G, et al. Callaghan JT, et al. Scand J Gastroenterol Suppl. 1987;136:9-17. doi: 10.3109/00365528709094480. Scand J Gastroenterol Suppl. 1987. PMID: 2892261 Review.
57 results